Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Crohn's disease
Biotech
Agomab uses $100M series C to push Crohn's drug through phase 2
A week after entering its lead asset into a phase 2 trial, Agomab has secured $100 million in series C financing to power up its pipeline.
James Waldron
Oct 11, 2023 8:50am
Sanofi pays Teva $500M to join red-hot bowel disease race
Oct 4, 2023 6:00am
AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral
Jun 1, 2023 6:10am
Takeda cuts 2 midstage GI assets in latest pipeline cleanup
May 11, 2023 7:42am
AbbVie closes cystic fibrosis chapter after combo 'did not work'
Apr 27, 2023 11:32am
Merck inks $11B Prometheus buyout to rival Roivant in IBD race
Apr 17, 2023 3:50am